Fig. 6: LINC01711 facilitates aerobic glycolysis in FAP⁺ CAFs and shields against CD8⁺ T cell attacks via the FGFR1/LDHA complex.

A–E ECAR assay, glucose uptake assay, lactate production assay and LDHA activity assay were performed in FAP+ CAFs transfected with si-LINC01711 or si-NC, treated with LDH inhibitor or not (n = 3 biological repeats). The P-value was calculated by two-tailed unpaired t-test. F–J. ECAR assay, glucose uptake assay, lactate production assay and LDHA activity assay were performed in FAP⁺ CAFs transfected with si-LINC01711 or si-NC, co-transfected with LDHA WT or LDHA mutant (n = 3 biological repeats). The P-value was calculated by two-tailed unpaired t-test. K–O ECAR assay, glucose uptake assay, lactate production assay and LDHA activity assay were performed in FAP⁺ CAFs transfected with si-LINC01711 or si-NC, co-transfected with si-FGFR1 or si-NC (n = 3 biological repeats). The P-value was calculated by two-tailed unpaired t-test. P Flow chart of in vitro co-culture model. Q Flow cytometry analysis on CD8-positive T cells infiltration, GZMB⁺ CD8-positive T cells infiltration and CD69⁺ CD8-positive T cells infiltration in in vitro co-culture model. R Flow chart of in vivo model. S Representative image of subcutaneous tumors. n = 5 biological repeats. T Tumor volume of subcutaneous tumors (n = 5 biological repeats, the P-value was determined by two-way ANOVA with Tukey’s multiple comparison test). U Tumor weight of subcutaneous tumors (n = 5 biological repeats, the P-value was calculated by two-tailed unpaired t-test). All the results were shown as mean ± S.E.M. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.